CureVac's mRNA coronavirus shot boasts one advantage over Pfizer and Moderna counterparts—refrigerated storage HHS partners with pharmacy chains, independent pharmacists to distribute COVID-19 vaccines AstraZeneca's Calquence fails COVID-19 study, joining the list of repurposed meds that have fallen short Fitch: COVID-19 accelerating insurers' financial headwinds Tapping GSK tech, Medicago kickstarts later-stage COVID vax tests Johnson & Johnson confident in 1B dose goal for COVID vaccine next year, looking ahead to 2022 Urban analysis: More than 3M lost employer insurance due to COVID-19 job losses COVID antibody drugs from Lilly and Regeneron won’t do much to boost their top lines: analysts J&J CEO Gorsky: COVID-19 vaccine makers aren't fighting each other. It's the virus that's the enemy Medical groups implore Congress to extend moratorium on sequester cuts as COVID-19 ramps up Biopharma roundup: CureVac's mRNA shot holds storage advantage; Medicago pushes into phase 3 Pfizer-BioNTech COVID vaccine data 'open the floodgates' for mRNA in infectious disease. Other areas? Not so fast: analysts Featured Story | By Eric Sagonowsky While Pfizer's COVID-19 vaccine turned in strong efficacy numbers and NIAID director Anthony Fauci said he expects similar figures from Moderna, the new class of mRNA shots mostly comes with stringent storage requirements that raise logistical hurdles to a broad rollout. Except CureVac, which now reports that its candidate is stable for up to three months at refrigerator temperatures. read more |
| |
|---|
|
Top Stories By Robert King HHS launched a major partnership with pharmacy chains and independent facilities to distribute a COVID-19 vaccine after it is approved. read more By Eric Sagonowsky Months after drugmakers launched an unprecedented COVID-19 research effort, some existing medicines have turned in promising results—but more of them have failed against the virus. And AstraZeneca’s blood cancer med Calquence just became one of them, falling short in a test in hospitalized patients. read more By Paige Minemyer The COVID-19 pandemic is accelerating trends impacting insurers' finances, in particular the interest in additional government control in the market, according to a new report from Fitch Ratings. read more By Ben Adams After signing up to use GlaxoSmithKline’s adjuvant vaccine technology back in the summer, Canadian biotech Medicago has already finished off a phase1, and is now kicking on with several phase 2/3 trials. read more By Fraiser Kansteiner As multiple COVID-19 shots edge close to the finish line, the focus is due to pivot to supply chain, Janssen's Paul Lefebvre figures. But thanks to J&J's expansive slate of manufacturing partners, the company is on track to meet its lofty manufacturing goals and has even started to weigh its pandemic plans for 2022. read more By Robert King An Urban Institute analysis finds more than 3 million people lost their employer-sponsored insurance, spelling changes to the payer mix for providers. read more By Arlene Weintraub Eli Lilly's COVID-19 antibody drug bamlanivimab won emergency authorization from the FDA with a label that's limited and potentially confusing, some analysts griped. Coupled with an expected onslaught of vaccines, those issues will likely suppress the potential market for antibody drugs from both Lilly and Regeneron, they said. read more By Eric Sagonowsky With COVID-19 vaccines and therapeutics rapidly moving ahead, Johnson & Johnson CEO Alex Gorsky said there's not a competition among drugmakers, but a cooperative, industrywide effort to defeat the pandemic. The best scenario, as outlined by Gorsky during a Detroit Economic Club event? "Four or five or six of these vaccines" available next year. read more By Robert King Payer and provider groups want Congress to extend a moratorium on Medicare sequester cuts that are now set to resume in January. read more By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner CureVac isn't a frontrunner in the mRNA vaccine field, but its shot holds one advantage over the leading players. Medicago is pushing its plant-derived candidate into phase 3, incorporating GSK's adjuvant technology. Plus, analysts flagged concerns about potential antibody revenues from Eli Lilly and Regeneron. read more By Angus Liu For an entirely new technology that hasn't seen a single approved product, Pfizer and BioNTech's COVID-19 vaccine victory showed mRNA can be quickly pivoted for a pandemic pathogen and will "open the floodgates" for its application in infectious disease. But other diseases? That could be a different story. read more |
